Moreover, the ability of the CaMKII inhibitor KN-93 can counteract the fibrotic remodeling induced by GF in type 2 diabetes, underscoring the functional importance of the CaMKII/Stat3 interaction in myocardial fibrosis. Here, CAMK2G is linked to Myocardial fibrosis.